Vericel Corporation
VCELInsider Trading
View AllVericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $237.22M | $197.52M | $164.37M | $156.18M | $124.18M | $117.85M | $90.86M | $63.92M |
| Cost of Revenue | $65.12M | $61.94M | $54.58M | $50.16M | $39.95M | $37.57M | $32.16M | $30.35M |
| Gross Profit | $172.11M | $135.58M | $109.79M | $106.03M | $84.23M | $80.28M | $58.70M | $33.57M |
| Gross Margin | 72.55% | 68.64% | 66.80% | 67.88% | 67.83% | 68.12% | 64.60% | 52.52% |
| Operating Expenses | $167.59M | $142.04M | $126.85M | $113.88M | $81.86M | $91.53M | $62.61M | $48.55M |
| Operating Income | $4.52M | $-6.46M | $-17.06M | $-7.85M | $2.37M | $-11.25M | $-3.91M | $-14.98M |
| Operating Margin | 1.90% | -3.27% | -10.38% | -5.03% | 1.91% | -9.55% | -4.30% | -23.44% |
| Net Income | $10.36M | $-3.18M | $-16.71M | $-7.47M | $2.86M | $-9.66M | $-8.14M | $-17.29M |
| Net Margin | 4.37% | -1.61% | -10.17% | -4.78% | 2.31% | -8.20% | -8.96% | -27.04% |
| EPS (Basic) | $0.21 | $-0.07 | $-0.35 | $-0.16 | $0.06 | $-0.18 | $-0.20 | $-0.52 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |